Skip to main content

Table 3 Safety summary in the Canadian subpopulation (All-Subjects-as-Treated)

From: Randomized controlled trial of ragweed sublingual immunotherapy tablet in the subpopulation of Canadian children and adolescents with allergic rhinoconjunctivitis

AE, No. (%)

Ragweed SLIT-tablet

(n = 117)*

Placebo

(n = 129)*

Treatment-emergent AE

108 (92.3)

96 (74.4)

Treatment-related AE

89 (76.1)

47 (36.4)

SAE

0

0

Treatment-related SAE

0

0

AE leading to treatment discontinuation

6 (5.1)

0

Treatment-related AE leading to treatment discontinuation

6 (5.1)

0

Discontinued treatment due to SAE

0

0

Discontinued treatment due to a treatment-related SAE

0

0

  1. AE adverse event, SAE serious adverse event
  2. *One subject randomized to placebo received the ragweed SLIT-tablet by mistake